Neurent Medical Secures €62.5 Million to Propel NEUROMARK Expansion
February 15, 2026, 9:38 pm
Neurent Medical secured a substantial €62.5 million Series C funding round. This capital accelerates commercial growth for its NEUROMARK System. The innovative technology targets chronic rhinitis, offering durable relief. It employs impedance-controlled radiofrequency to address underlying causes. Funds expand market access, broaden clinical evidence, and advance product development. This major investment underscores confidence in Neurent Medical's impact on sinonasal disease treatment, promising better patient outcomes and significant market penetration in the MedTech sector.
Neurent Medical, a vanguard in medical technology, has closed an oversubscribed Series C financing round. The company secured an impressive €62.5 million, equivalent to $74 million. This significant capital infusion targets the robust commercial expansion of its NEUROMARK System. The innovative device treats chronic rhinitis, a widespread and debilitating condition. Funding also broadens clinical evidence generation and accelerates product pipeline advancement. This strategic investment positions Neurent Medical for substantial growth and market leadership in sinonasal disease solutions.
Chronic rhinitis impacts millions worldwide. Patients endure persistent symptoms like nasal congestion, excessive discharge, sneezing, and postnasal drip. These symptoms significantly diminish quality of life. Current treatments often offer temporary relief or fail to address the underlying cause. A clear need exists for durable, effective solutions. Neurent Medical developed the NEUROMARK System to meet this critical demand.
The NEUROMARK System utilizes proprietary Impedance Controlled Radiofrequency technology. This advanced approach targets overactive posterior nasal nerves. These nerves drive the persistent symptoms of chronic rhinitis. The technology provides clinicians with real-time feedback during procedures. This feedback ensures precision and confidence. The system offers a differentiated and durable treatment option. It directly addresses the root cause of the condition, not merely its symptoms. This marks a paradigm shift in chronic rhinitis management.
MVM Partners led the latest financing round. Sofinnova Partners provided significant participation. Existing investors also continued their support. These included EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland. Their sustained commitment highlights strong belief in Neurent Medical's vision and technology. The oversubscribed nature of the round further indicates high investor confidence. Neurent Medical’s strategic importance within the European MedTech landscape is clear.
The newly secured capital has multiple critical applications. A primary focus is scaling commercial operations. This includes expanding patient access to NEUROMARK. Broader market penetration is a key objective. Neurent Medical plans to bolster its sales and marketing infrastructure. This will bring the NEUROMARK System to more physicians and patients in need. The company maintains its headquarters in Galway, Ireland, with crucial U.S. operations in Braintree, Massachusetts. This dual presence supports global expansion efforts.
Further evidence development forms another core use of funds. Generating robust clinical data is paramount. This supports broader patient populations and reinforces the system's efficacy. Strong clinical validation is essential for widespread adoption. It builds trust among healthcare providers and patients. This commitment to evidence-based medicine solidifies NEUROMARK's market position.
Pipeline development also benefits from this investment. Neurent Medical plans to continue building out its product pipeline. This includes exploring potential expansion of the platform. New indications beyond chronic rhinitis are under investigation. This forward-looking strategy ensures sustained innovation. It positions Neurent Medical as a long-term leader in medical device development.
The company's board of directors sees new additions. Kyle Dempsey, a Partner at MVM Partners, joins the board. Cedric Moreau, a Partner at Sofinnova Partners, also takes a seat. These individuals bring extensive expertise in MedTech investing and strategic growth. Their guidance will be invaluable as Neurent Medical navigates its commercial expansion. Their presence underscores the strategic nature of this investment.
Posterior nasal nerve ablation is an emerging treatment category. It offers powerful relief for chronic rhinitis sufferers. NEUROMARK sets a new standard within this rapidly evolving field. Its proprietary impedance control system is a key differentiator. It delivers real-time feedback. This provides clinicians with greater treatment confidence, control, and predictability. The approach aims for minimal downtime and a strong safety profile.
This financing round places Neurent Medical at the higher end of European MedTech fundraising. This highlights investor belief in clinically validated devices. Such devices address chronic conditions with limited existing options. Neurent Medical's technology promises meaningful and durable patient benefits. Its differentiated approach is supported by a growing body of clinical evidence. The potential for platform expansion into additional indications excites investors.
Neurent Medical's mission since inception has been clear. It seeks to meaningfully improve patients' lives. It also aims to empower ENT physicians with predictable, minimally invasive care. This investment significantly advances that mission. It represents a pivotal stage of commercial growth. The company is poised to transform the treatment landscape for chronic inflammatory sinonasal diseases. The future of chronic rhinitis treatment looks brighter with NEUROMARK.
Neurent Medical, a vanguard in medical technology, has closed an oversubscribed Series C financing round. The company secured an impressive €62.5 million, equivalent to $74 million. This significant capital infusion targets the robust commercial expansion of its NEUROMARK System. The innovative device treats chronic rhinitis, a widespread and debilitating condition. Funding also broadens clinical evidence generation and accelerates product pipeline advancement. This strategic investment positions Neurent Medical for substantial growth and market leadership in sinonasal disease solutions.
Chronic rhinitis impacts millions worldwide. Patients endure persistent symptoms like nasal congestion, excessive discharge, sneezing, and postnasal drip. These symptoms significantly diminish quality of life. Current treatments often offer temporary relief or fail to address the underlying cause. A clear need exists for durable, effective solutions. Neurent Medical developed the NEUROMARK System to meet this critical demand.
The NEUROMARK System utilizes proprietary Impedance Controlled Radiofrequency technology. This advanced approach targets overactive posterior nasal nerves. These nerves drive the persistent symptoms of chronic rhinitis. The technology provides clinicians with real-time feedback during procedures. This feedback ensures precision and confidence. The system offers a differentiated and durable treatment option. It directly addresses the root cause of the condition, not merely its symptoms. This marks a paradigm shift in chronic rhinitis management.
MVM Partners led the latest financing round. Sofinnova Partners provided significant participation. Existing investors also continued their support. These included EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland. Their sustained commitment highlights strong belief in Neurent Medical's vision and technology. The oversubscribed nature of the round further indicates high investor confidence. Neurent Medical’s strategic importance within the European MedTech landscape is clear.
The newly secured capital has multiple critical applications. A primary focus is scaling commercial operations. This includes expanding patient access to NEUROMARK. Broader market penetration is a key objective. Neurent Medical plans to bolster its sales and marketing infrastructure. This will bring the NEUROMARK System to more physicians and patients in need. The company maintains its headquarters in Galway, Ireland, with crucial U.S. operations in Braintree, Massachusetts. This dual presence supports global expansion efforts.
Further evidence development forms another core use of funds. Generating robust clinical data is paramount. This supports broader patient populations and reinforces the system's efficacy. Strong clinical validation is essential for widespread adoption. It builds trust among healthcare providers and patients. This commitment to evidence-based medicine solidifies NEUROMARK's market position.
Pipeline development also benefits from this investment. Neurent Medical plans to continue building out its product pipeline. This includes exploring potential expansion of the platform. New indications beyond chronic rhinitis are under investigation. This forward-looking strategy ensures sustained innovation. It positions Neurent Medical as a long-term leader in medical device development.
The company's board of directors sees new additions. Kyle Dempsey, a Partner at MVM Partners, joins the board. Cedric Moreau, a Partner at Sofinnova Partners, also takes a seat. These individuals bring extensive expertise in MedTech investing and strategic growth. Their guidance will be invaluable as Neurent Medical navigates its commercial expansion. Their presence underscores the strategic nature of this investment.
Posterior nasal nerve ablation is an emerging treatment category. It offers powerful relief for chronic rhinitis sufferers. NEUROMARK sets a new standard within this rapidly evolving field. Its proprietary impedance control system is a key differentiator. It delivers real-time feedback. This provides clinicians with greater treatment confidence, control, and predictability. The approach aims for minimal downtime and a strong safety profile.
This financing round places Neurent Medical at the higher end of European MedTech fundraising. This highlights investor belief in clinically validated devices. Such devices address chronic conditions with limited existing options. Neurent Medical's technology promises meaningful and durable patient benefits. Its differentiated approach is supported by a growing body of clinical evidence. The potential for platform expansion into additional indications excites investors.
Neurent Medical's mission since inception has been clear. It seeks to meaningfully improve patients' lives. It also aims to empower ENT physicians with predictable, minimally invasive care. This investment significantly advances that mission. It represents a pivotal stage of commercial growth. The company is poised to transform the treatment landscape for chronic inflammatory sinonasal diseases. The future of chronic rhinitis treatment looks brighter with NEUROMARK.